Powell speech takes center stage in Tuesday’s economic events
Southpoint Capital Advisors LP, a ten percent owner of Fennec Pharmaceuticals Inc (NASDAQ:FENC), reported selling shares of common stock over three days for a total value of $636228. The sales occurred between October 7 and October 9, 2025. The insider selling comes as FENC trades near its 52-week high of $9.92, having delivered an impressive 84% return over the past six months. According to InvestingPro analysis, the company maintains strong gross margins of ~90%.
On October 7, Southpoint sold 26,900 shares with prices ranging from $9.47 to $9.70, at a weighted average price of $9.5871. On October 8, the firm sold 19,605 shares in multiple transactions, with prices ranging from $9.31 to $9.61, at a weighted average price of $9.4732. The final sale occurred on October 9, with 20,609 shares sold, prices ranging from $9.30 to $9.42, at a weighted average price of $9.3461. With a market capitalization of $261 million, analysts maintain a bullish outlook on FENC, setting price targets between $13 and $15.
Following these transactions, Southpoint Master Fund, LP, indirectly holds 4,010,100 shares of Fennec Pharmaceuticals. For deeper insights into FENC’s valuation and 10+ additional ProTips, visit InvestingPro, where you’ll find comprehensive analysis and Fair Value estimates in our detailed Pro Research Report.
In other recent news, Fennec Pharmaceuticals reported its second-quarter 2025 financial results, which fell short of expectations. The company announced an earnings per share (EPS) of -$0.11, significantly missing the forecasted -$0.04. However, Fennec Pharmaceuticals did report a revenue of $9.65 million, which was a 2.77% surprise above what analysts had anticipated. Despite this positive revenue outcome, the market reacted negatively due to the earnings miss. This earnings report has been a key focus for investors and analysts alike.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.